Yahoo Finance

Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study

TAIPEI, Taiwan and SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study for ...
Yahoo Finance

Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)

TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that ...
Business Wire

Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial

LARKSPUR, Calif.--(BUSINESS WIRE)--Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global ...
Hosted on MSN

Polaris Industries’ Promising Study on ADI-PEG 20 for Liver Cancer

Polaris Industries ((PII)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Pharmabiz

Polaris seeks US FDA approval to begin phase 1 trial of ADI-PEG 20 to treat leukaemia

Polaris Group, a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases, has filed an ...